Bayer AG NA (BAYN) - Net Assets
Based on the latest financial reports, Bayer AG NA (BAYN) has net assets worth €29.70 Billion EUR as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€104.21 Billion) and total liabilities (€74.51 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €29.70 Billion |
| % of Total Assets | 28.5% |
| Annual Growth Rate | 3.6% |
| 5-Year Change | 4.38% |
| 10-Year Change | 25.94% |
| Growth Volatility | 15.48 |
Bayer AG NA - Net Assets Trend (1998–2024)
This chart illustrates how Bayer AG NA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bayer AG NA (1998–2024)
The table below shows the annual net assets of Bayer AG NA from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €32.05 Billion | -3.12% |
| 2023-12-31 | €33.08 Billion | -15.02% |
| 2022-12-31 | €38.93 Billion | +17.36% |
| 2021-12-31 | €33.17 Billion | +8.04% |
| 2020-12-31 | €30.70 Billion | -35.39% |
| 2019-12-31 | €47.52 Billion | +2.97% |
| 2018-12-31 | €46.15 Billion | +25.19% |
| 2017-12-31 | €36.86 Billion | +15.56% |
| 2016-12-31 | €31.90 Billion | +25.36% |
| 2015-12-31 | €25.45 Billion | +25.85% |
| 2014-12-31 | €20.22 Billion | -2.82% |
| 2013-12-31 | €20.80 Billion | +12.04% |
| 2012-12-31 | €18.57 Billion | -3.64% |
| 2011-12-31 | €19.27 Billion | +1.98% |
| 2010-12-31 | €18.90 Billion | -0.29% |
| 2009-12-31 | €18.95 Billion | +15.98% |
| 2008-12-31 | €16.34 Billion | -2.86% |
| 2007-12-31 | €16.82 Billion | +30.89% |
| 2006-12-31 | €12.85 Billion | +17.85% |
| 2005-12-31 | €10.90 Billion | -11.84% |
| 2004-12-31 | €12.37 Billion | +0.45% |
| 2003-12-31 | €12.31 Billion | -20.39% |
| 2002-12-31 | €15.47 Billion | -9.27% |
| 2001-12-31 | €17.05 Billion | +3.82% |
| 2000-12-31 | €16.42 Billion | +8.17% |
| 1999-12-31 | €15.18 Billion | +18.80% |
| 1998-12-31 | €12.78 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bayer AG NA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 38.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.87 Billion | 30.92% |
| Common Stock | €2.52 Billion | 7.88% |
| Other Comprehensive Income | €19.53 Billion | 61.19% |
| Total Equity | €31.91 Billion | 100.00% |
Bayer AG NA Competitors by Market Cap
The table below lists competitors of Bayer AG NA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Carvana Co
NYSE:CVNA
|
$45.32 Billion |
|
ASSA ABLOY AB ser. B
LSE:0R87
|
$45.34 Billion |
|
CSL Limited
F:CSJ
|
$45.38 Billion |
|
Occidental Petroleum Corporation
NYSE:OXY
|
$45.39 Billion |
|
Becton Dickinson and Company
NYSE:BDX
|
$45.10 Billion |
|
CBRE Group Inc Class A
NYSE:CBRE
|
$45.09 Billion |
|
Ciena Corp
NYSE:CIEN
|
$45.06 Billion |
|
Compagnie de Saint-Gobain S.A.
PA:SGO
|
$45.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bayer AG NA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 32,927,000,000 to 31,908,000,000, a change of -1,019,000,000 (-3.1%).
- Net loss of 2,552,000,000 reduced equity.
- Dividend payments of 131,000,000 reduced retained earnings.
- Share repurchases of 16,000,000 reduced equity.
- Other comprehensive income increased equity by 19,550,000,000.
- Other factors decreased equity by 17,870,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.55 Billion | -8.0% |
| Dividends Paid | €131.00 Million | -0.41% |
| Share Repurchases | €16.00 Million | -0.05% |
| Other Comprehensive Income | €19.55 Billion | +61.27% |
| Other Changes | €-17.87 Billion | -56.0% |
| Total Change | €- | -3.09% |
Book Value vs Market Value Analysis
This analysis compares Bayer AG NA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.39x to 1.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | €17.21 | €41.10 | x |
| 1999-12-31 | €20.54 | €41.10 | x |
| 2000-12-31 | €22.13 | €41.10 | x |
| 2001-12-31 | €23.22 | €41.10 | x |
| 2002-12-31 | €20.98 | €41.10 | x |
| 2003-12-31 | €18.05 | €41.10 | x |
| 2004-12-31 | €16.78 | €41.10 | x |
| 2005-12-31 | €14.82 | €41.10 | x |
| 2006-12-31 | €16.12 | €41.10 | x |
| 2007-12-31 | €20.31 | €41.10 | x |
| 2008-12-31 | €19.73 | €41.10 | x |
| 2009-12-31 | €22.88 | €41.10 | x |
| 2010-12-31 | €22.77 | €41.10 | x |
| 2011-12-31 | €23.23 | €41.10 | x |
| 2012-12-31 | €22.33 | €41.10 | x |
| 2013-12-31 | €25.05 | €41.10 | x |
| 2014-12-31 | €24.31 | €41.10 | x |
| 2015-12-31 | €29.34 | €41.10 | x |
| 2016-12-31 | €36.44 | €41.10 | x |
| 2017-12-31 | €41.57 | €41.10 | x |
| 2018-12-31 | €48.87 | €41.10 | x |
| 2019-12-31 | €48.22 | €41.10 | x |
| 2020-12-31 | €31.07 | €41.10 | x |
| 2021-12-31 | €33.61 | €41.10 | x |
| 2022-12-31 | €39.47 | €41.10 | x |
| 2023-12-31 | €33.52 | €41.10 | x |
| 2024-12-31 | €32.48 | €41.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bayer AG NA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.48%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 3.47x
- Recent ROE (-8.00%) is below the historical average (7.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 12.84% | 5.75% | 0.96x | 2.34x | €357.20 Million |
| 1999 | 13.34% | 7.33% | 0.87x | 2.08x | €501.40 Million |
| 2000 | 10.29% | 5.63% | 0.81x | 2.26x | €46.74 Million |
| 2001 | 5.70% | 3.33% | 0.78x | 2.19x | €-728.63 Million |
| 2002 | 6.91% | 3.66% | 0.69x | 2.72x | €-474.20 Million |
| 2003 | -10.32% | -4.41% | 0.76x | 3.07x | €-2.48 Billion |
| 2004 | 4.92% | 2.03% | 0.79x | 3.08x | €-623.19 Million |
| 2005 | 14.73% | 5.83% | 0.75x | 3.39x | €511.65 Million |
| 2006 | 13.28% | 5.85% | 0.52x | 4.38x | €418.24 Million |
| 2007 | 28.15% | 14.55% | 0.63x | 3.07x | €3.04 Billion |
| 2008 | 10.57% | 5.22% | 0.63x | 3.23x | €92.70 Million |
| 2009 | 7.19% | 4.36% | 0.61x | 2.70x | €-530.70 Million |
| 2010 | 6.91% | 3.71% | 0.68x | 2.73x | €-582.30 Million |
| 2011 | 12.86% | 6.76% | 0.69x | 2.75x | €548.80 Million |
| 2012 | 13.24% | 6.15% | 0.77x | 2.78x | €599.10 Million |
| 2013 | 15.39% | 7.94% | 0.78x | 2.48x | €1.12 Billion |
| 2014 | 17.04% | 8.11% | 0.60x | 3.49x | €1.42 Billion |
| 2015 | 16.94% | 8.87% | 0.63x | 3.05x | €1.68 Billion |
| 2016 | 14.94% | 9.69% | 0.57x | 2.71x | €1.50 Billion |
| 2017 | 19.93% | 20.95% | 0.47x | 2.04x | €3.66 Billion |
| 2018 | 3.69% | 4.28% | 0.31x | 2.75x | €-2.90 Billion |
| 2019 | 5.13% | 5.58% | 0.34x | 2.67x | €-2.30 Billion |
| 2020 | -50.98% | -37.59% | 0.35x | 3.83x | €-18.61 Billion |
| 2021 | 3.03% | 2.27% | 0.37x | 3.64x | €-2.30 Billion |
| 2022 | 10.70% | 8.18% | 0.41x | 3.22x | €272.70 Million |
| 2023 | -8.93% | -6.17% | 0.41x | 3.53x | €-6.23 Billion |
| 2024 | -8.00% | -5.48% | 0.42x | 3.47x | €-5.74 Billion |
Industry Comparison
This section compares Bayer AG NA's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,342,709,197,064
- Average return on equity (ROE) among peers: 13.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bayer AG NA (BAYN) | €29.70 Billion | 12.84% | 2.51x | $45.18 Billion |
| Bayer Aktiengesellschaft (BAYA) | $31.90 Billion | 14.21% | 1.58x | $38.90 Billion |
| Chugai Pharmaceutical Co., Ltd. (CUP0) | $1.42 Trillion | 26.29% | 0.31x | $76.91 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $33.87 Billion | 12.78% | 0.31x | $10.18 Billion |
| EH3 (EH3) | $459.28 Million | -8.45% | 0.46x | $258.63 Million |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $52.41 Billion | 7.20% | 0.81x | $459.04 Million |
| PT Kalbe Farma Tbk (LCLA) | $8.50 Trillion | 22.58% | 0.33x | $2.09 Billion |
| Ono Pharmaceutical Co. Ltd (ON4) | $529.62 Billion | 9.49% | 0.15x | $6.58 Billion |
| Otsuka Holdings Co. Ltd (OS1) | $1.51 Trillion | 9.99% | 0.34x | $25.67 Billion |
| Recordati Industria Chimica e Farmaceutica S.p.A (RER1) | $1.03 Billion | 28.11% | 1.00x | $10.43 Billion |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more